|
Coronary Artery Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
MMP-3 was higher in acute MI versus stable CAD subjects at the time of acute MI: (453 vs. 217 pg/mL, p = 0.010) but not at quiescent phase follow-up (p > 0.05).
|
31808123 |
2020 |
|
Coronary Artery Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This examination, as the first study of its own kind in Iranian Turks, reported association between MMP-1 (rs1799750) -1607 2G/2G and MMP-3 (rs3025058) -1612 6A/6A genotypes and CAD risk in patients older than 50 years.
|
31356534 |
2019 |
|
Coronary Artery Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
MMP-3 baseline level in patients with history of CAD is a potential predictor for cardiovascular outcomes.
|
31218540 |
2019 |
|
Coronary Artery Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Although results thus far are inconsistent, meta-analysis has demonstrated that MMP-3 Glu45Lys and MMP-9 1562C/T gene polymorphisms were associated with CAD risk.
|
24938016 |
2014 |
|
Coronary Artery Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Within this context, our aim was to examine whether MMP1, MMP3, and MMP9 gene polymorphisms are associated with susceptibility to acute coronary syndrome (ACS) or angiographic coronary artery disease (CAD).
|
23377317 |
2013 |
|
Coronary Artery Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The results provided strong evidence regarding the susceptibility of MMP3 and MMP9 genes to the development of CAD.
|
22689717 |
2012 |
|
Coronary Artery Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Haplotypes and 5A/6A polymorphism of the matrix metalloproteinase-3 gene in coronary disease: case-control study and a meta-analysis.
|
19762026 |
2010 |
|
Coronary Artery Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to analyze the occurrence of the -1612 5A/6A, -376C/G, and Glu45Lys polymorphisms of MMP3 and the -1562C/T and R279Q polymorphisms of MMP9 and their relation to the risk of coronary heart disease (CHD; stenosis >/=50% of the diameter in at least one major coronary artery) in a Chinese Han population.
|
19438845 |
2009 |
|
Coronary Artery Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The combined PON1 55/192 and MMP-3 5A/6A genetic variants are associated with CAD; PON1 seems to be connected with the number of diseased vessels, and hypertension and hyperlipidemia are related with PON1 192 and MMP-3 in CAD patients.
|
18830194 |
2008 |
|
Coronary Artery Disease
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
The combined PON1 55/192 and MMP-3 5A/6A genetic variants are associated with CAD; PON1 seems to be connected with the number of diseased vessels, and hypertension and hyperlipidemia are related with PON1 192 and MMP-3 in CAD patients.
|
18830194 |
2008 |
|
Coronary Artery Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Matrix metalloproteinase-3 and coronary remodelling: implications for unstable coronary disease.
|
17543900 |
2007 |
|
Coronary Artery Disease
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Plasma concentrations/activities of MMP-2 and MMP-9 were also measured, as were plasma concentrations of MMP-3, TIMP-1, and TIMP-2 in 80 patients (49 with ACSs and 31 with stable CAD) and 40 controls.
|
17320799 |
2007 |
|
Coronary Artery Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Composite MMP-9 genotypes but not other SNPs were associated with MI, whereas MMP-1/MMP-3 genotypes were CAD-associated.
|
17893005 |
2007 |
|
Coronary Artery Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Matrix metalloproteinase-3 (MMP-3) is implicated in the formation of atherosclerotic plaques, and the MMP-3 -1612 5A/6A polymorphism is associated with myocardial infarction (MI) and stable coronary artery disease (CAD).
|
16238676 |
2005 |
|
Coronary Artery Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We found no association between the 5A/6A polymorphism in the MMP-3 gene and risk of coronary heart disease.
|
14499230 |
2003 |
|
Coronary Artery Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to assess matrix metalloproteinase-3 (MMP3) gene variation in relation to the degree of coronary atherosclerosis and risk of myocardial infarction (MI) in patients with coronary artery disease.
|
12821236 |
2003 |
|
Coronary Artery Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Multivariate logistic regression analysis, with adjustment for age, body mass index, and the prevalence of smoking and hyperuricemia, revealed that the -219G-->T polymorphism of the apolipoprotein E gene in low-risk men, the -1171/5A-->6A polymorphism of the stromelysin-1 gene in low-risk women, the 1019C-->T polymorphism of the connexin 37 gene in high-risk men, and the 3932T-->C polymorphism of the apolipoprotein E gene in high-risk women were significantly associated with CAD.
|
14563588 |
2003 |
|
Coronary Artery Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Interaction between smoking and the stromelysin-1 (MMP3) gene 5A/6A promoter polymorphism and risk of coronary heart disease in healthy men.
|
12485468 |
2002 |
|
Coronary Artery Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The stromelysin-1 5A/6A promoter polymorphism is a disease marker for the extent of coronary heart disease.
|
12515907 |
2002 |
|
Coronary Artery Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In a study of 213 healthy individuals and 105 patients with coronary artery disease (CAD), we examined whether stromelysin-1 (MMP-3) genotype, determined by the 5A/6A promoter polymorphism, influences large artery stiffening.
|
11903311 |
2001 |
|
Coronary Artery Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The functional 5A/6A polymorphism of the stromelysin-1 promoter has been implicated as a potential genetic marker for the progression of angiographically determined atherosclerosis in patients with coronary artery disease.
|
11116068 |
2000 |
|
Coronary Artery Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The stromelysin-1 genotype was determined for 496 men with coronary artery disease and cholesterol levels between 4.0 and 8.0 mmol/L, participating in the Regression Growth Evaluation Statin Study (REGRESS) study, a clinical trial assessing the effect of the lipid-lowering drug pravastatin on the progression of atherosclerosis.
|
10190398 |
1999 |
|
Coronary Artery Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study. Lopid Coronary Angiography Trial.
|
9699891 |
1998 |
|
Coronary Artery Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Thus, the common 5A/6A polymorphism of the human stromelysin-1 promoter appears to play an important role in regulating stromelysin-1 gene expression and may be involved in the progression of coronary heart disease.
|
8662692 |
1996 |
|
Coronary Artery Disease
|
0.400 |
Biomarker
|
disease |
CTD_human |
Thus, the common 5A/6A polymorphism of the human stromelysin-1 promoter appears to play an important role in regulating stromelysin-1 gene expression and may be involved in the progression of coronary heart disease.
|
8662692 |
1996 |